The European Medicines Agency has received 11 new marketing authorization applications (MAAs) from companies seeking pan-EU approval for their products, including two applications covering Janssen’s investigational two-dose Ebola vaccine regimen, both of which have been granted fast-track review.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?